がん治療薬市場：薬剤クラス別、投与経路別、分子タイプ別、適応症別、エンドユーザー別、流通チャネル別-2025-2030年の世界予測

がん治療薬市場の2024年の市場規模は2,100億米ドルで、2025年には2,255億4,000万米ドル、CAGR 7.72%で成長し、2030年には3,281億6,000万米ドルに達すると予測されています。

がん治療薬市場は近年目覚ましい進化を遂げ、世界のヘルスケア分野で最もダイナミックで競争力のある分野の一つとして台頭してきました。バイオテクノロジーの進歩と、がん生物学に対する理解の深まりにより、革新的な治療法への道が開かれ、がん医療における従来のパラダイムが再定義されつつあります。この急速に進化する状況の中で、臨床医から意思決定者までの利害関係者は、現在の動向を反映するだけでなく、将来の機会を予測する洞察を絶えず求めています。臨床転帰の開発、規制政策の転換、最先端研究のすべてが、この業界を前進させる一因となっています。本レポートでは、市場の多面的な側面を掘り下げ、変革的な変化、セグメンテーションのニュアンス、地域市場のバリエーション、競合力学を詳細に分析し、業界リーダーのための実用的なガイダンスを提供します。専門家と熟練した専門家の両方に対応するバランスの取れた詳細な視点を提供することで、以下のセクションでは、がん治療薬の将来を形作る劇的な変化に光を当てています。

がん治療薬市場の変革

近年、科学的ブレークスルーと戦略的パートナーシップによって治療法が再定義されるなど、がん治療薬の状況は大きく変化しています。プレシジョン・メディシンの統合とゲノム・プロファイリングの進歩は治療選択に革命をもたらし、治療効果を高める個別化アプローチを可能にしました。薬剤開発における革新は、標的治療薬や免疫腫瘍治療薬の出現につながり、これらは生存率を向上させただけでなく、従来の化学療法と比較して毒性も減少させました。さらに、患者中心の治療への関心の高まりが、コンプライアンスと全体的な転帰を改善する新たな投与方法の採用を後押ししています。世界中の規制機関が画期的な治療法の評価プロセスを加速させているため、有望な化合物の市場参入が加速しています。このパラダイムシフトは、研究開発への旺盛な投資、実臨床でのエビデンスの重視、学界と産業界の共同イニシアティブによって特徴づけられます。このような変化により、競合情勢と革新的な市場情勢が整いつつあり、多様な患者集団の進化する需要に応える態勢が整いつつあります。

市場力学を牽引する主なセグメンテーション洞察

がん治療薬市場は、さまざまな治療・商業セグメントを詳細に把握できる複雑なセグメンテーションの枠組みによって区別されます。薬剤クラス別では、化学療法剤、ホルモン療法剤、免疫療法剤、標的治療剤が分析対象となります。化学療法剤では、アルキル化剤と代謝拮抗剤の詳細な評価により、臨床判断に影響を与える有効性と毒性プロファイルに関する重要な洞察が得られます。免疫療法剤はさらにCAR T細胞療法とチェックポイント阻害剤に区分され、CTLA-4阻害剤とPD-1/PD-L1阻害剤に焦点を当て、免疫応答の調節におけるそれぞれの役割の違いを強調しています。標的治療の領域では、モノクローナル抗体（キメラ抗体とヒト化抗体の区別あり）、低分子阻害剤についてさらに精査が行われ、サイクリン依存性キナーゼ阻害剤とチロシンキナーゼ阻害剤のニュアンスに富んだレビューは、薬力学を理解する上で不可欠です。さらに、投与経路に基づくセグメンテーションにより、筋肉内、静脈内、皮下などの注射製剤と経口療法が区別されます。分子の種類による評価では、モノクローナル抗体やワクチンで構成される生物製剤と低分子製剤の性能と用途が対比されます。適応症に基づくセグメンテーションは、血液、乳房、大腸、肺、前立腺に至るまで様々ながんを網羅し、血液がんではさらに白血病とリンパ腫に分け、急性骨髄性白血病、慢性リンパ性白血病、ホジキンリンパ腫、非ホジキンリンパ腫ではさらに深く区別しています。病院、研究機関、専門クリニックを含むエンドユーザーセグメンテーションや、病院薬局、オンライン薬局、小売薬局を区別する流通チャネルにも洞察を広げています。この包括的なパノラマは、市場の異質性を強調すると同時に、利害関係者に戦略的意思決定に必要な的を絞った洞察を提供します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん治療薬に対する有利な償還政策を通じて政府の支援を増強する
    • 公的部門と民間部門の両方からがん研究開発活動への投資が増加
    • 世界中でさまざまな種類のがんの罹患率が上昇しており、腫瘍治療薬の開発の急増が求められています。
  • 抑制要因
    • がん治療に伴う副作用
  • 機会
    • 革新的ながん治療薬の開発を加速するためにバイオテクノロジー企業との連携を強化
    • 遠隔医療と腫瘍学の実践を統合し、十分な医療を受けられていない遠隔地の患者集団に到達する
  • 課題
    • 腫瘍薬の試験実施に伴う複雑さ
• 市場セグメンテーション分析
  • 投与経路：化学療法剤を迅速に送達できるため、注射経路が好まれる傾向が高まっています。
  • エンドユーザー：がん患者の数の増加により、病院でのがん治療薬の使用が増加しています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 がん治療薬市場薬剤クラス別

• 化学療法剤
  • アルキル化剤
  • 代謝拮抗剤
• ホルモン療法剤
• 免疫療法剤
  • CAR T細胞療法
  • チェックポイント阻害剤
    • CTLA-4阻害剤
    • PD-1/PD-L1阻害剤
• 標的治療薬
  • モノクローナル抗体
    • キメラ
    • 人間化
  • 低分子阻害剤
    • サイクリン依存性キナーゼ阻害剤
    • チロシンキナーゼ阻害剤

第7章 がん治療薬市場：投与経路別

• 注射剤
  • 筋肉内
  • 静脈内
  • 皮下
• オーラル

第8章 がん治療薬市場分子タイプ別

• 生物学的製剤
  • モノクローナル抗体
  • ワクチン
• 小分子

第9章 がん治療薬市場：適応症別

• 血液がん
  • 白血病
    • 急性骨髄性白血病
    • 慢性リンパ性白血病
  • リンパ腫
    • ホジキンリンパ腫
    • 非ホジキンリンパ腫
• 乳がん
• 大腸がん
• 肺がん
• 前立腺がん

第10章 がん治療薬市場：エンドユーザー別

• 病院
• 調査機関
• 専門クリニック

第11章 がん治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第12章 南北アメリカのがん治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域のがん治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのがん治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Agenus Inc.
• Amgen Inc.
• Apres-demain SA
• Aspen Pharmacare Holdings Limited
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• BeiGene, Inc.
• Bristol-Myers Squibb Company
• C.H. Boehringer Sohn AG & Co. KG
• Cipla Limited
• Eli Lilly and Company
• GSK plc
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Pfizer Inc.
• Puma Biotechnology, Inc.
• Roche Holding AG
• Shorla Oncology
• Sun Pharmaceutical Industries Ltd
• Sutro Biopharma, Inc.
• Takeda Pharmaceutical Company Limited
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. ONCOLOGY DRUGS MARKET MULTI-CURRENCY
• FIGURE 2. ONCOLOGY DRUGS MARKET MULTI-LANGUAGE
• FIGURE 3. ONCOLOGY DRUGS MARKET RESEARCH PROCESS
• FIGURE 4. ONCOLOGY DRUGS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ONCOLOGY DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 60. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 61. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 62. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 64. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 65. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 66. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 68. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 69. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 70. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 71. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 72. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 73. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 75. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 77. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 79. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 80. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 81. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 86. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 87. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 88. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 89. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 90. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 91. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 93. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 95. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 97. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 98. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 99. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 103. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 104. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 105. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 106. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 107. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 108. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 110. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 112. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 114. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 115. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 116. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. CANADA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 120. CANADA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 121. CANADA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 122. CANADA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 123. CANADA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 124. CANADA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 125. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 127. CANADA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 128. CANADA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 129. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. CANADA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 131. CANADA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 132. CANADA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 133. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 136. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 137. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 138. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 139. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 140. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 141. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 142. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 144. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 146. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 148. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 149. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 150. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 153. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 154. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 155. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 156. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 157. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 158. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 159. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 161. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 162. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 163. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 165. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 166. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 167. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 170. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 171. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 172. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 173. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 174. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 175. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 176. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 177. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 179. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 180. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 181. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 182. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 183. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 184. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 185. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 188. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 189. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 190. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 191. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 192. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 193. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 194. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 195. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 196. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 197. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 198. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 199. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 200. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 201. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 202. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 203. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 204. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 205. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 206. CHINA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 207. CHINA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 208. CHINA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 209. CHINA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 210. CHINA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 211. CHINA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 212. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 213. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 214. CHINA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 215. CHINA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 216. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 217. CHINA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 218. CHINA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 219. CHINA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 220. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 221. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 222. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 223. INDIA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 224. INDIA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 225. INDIA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 226. INDIA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 227. INDIA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 228. INDIA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 229. INDIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 231. INDIA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 232. INDIA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 233. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 234. INDIA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 235. INDIA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 236. INDIA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 237. INDIA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 238. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 239. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 240. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 241. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 242. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 243. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 244. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 245. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 246. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 247. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 248. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 249. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 250. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 251. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 252. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 253. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 254. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 255. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 256. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 257. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 258. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 259. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 260. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 261. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 262. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 263. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 264. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 265. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 266. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 267. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 268. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 269. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 270. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 271. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 272. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 273. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 274. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 275. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 276. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 277. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 278. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 279. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 280. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 281. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 282. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 283. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 284. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 285. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 286. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 287. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 288. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 289. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 290. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 291. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 292. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 293. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 294. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 295. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 296. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 297. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 298. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 299. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 300. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 301. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 302. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 303. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 304. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 305. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 306. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 307. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 308. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 309. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 310. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 311. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 312. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 313. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 314. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 315. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 316. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 317. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 318. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 319. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 320. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 321. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 322. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 323. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 324. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 325. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 326. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 327. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 328. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 329. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 330. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 331. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 332. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 333. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 334. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 335. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 336. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 337. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
• TABLE 338. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
• TABLE 339. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 340. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 341. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 342. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 343. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 344. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 345. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
• TABLE 346. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 347. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 348. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 349. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 350. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 351. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 352. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 353. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
• TABLE 354. TAIWAN ONCOLOGY

The Oncology Drugs Market was valued at USD 210.00 billion in 2024 and is projected to grow to USD 225.54 billion in 2025, with a CAGR of 7.72%, reaching USD 328.16 billion by 2030.

The oncology drugs market has witnessed a remarkable evolution over recent years, emerging as one of the most dynamic and competitive sectors in the global healthcare arena. Advances in biotechnology and an increasingly robust understanding of cancer biology have paved the way for innovative treatment options that are now redefining traditional paradigms in oncology care. In this rapidly evolving landscape, stakeholders from clinicians to decision-makers are continuously seeking insights that not only reflect current trends but also forecast future opportunities. The developments in clinical outcomes, regulatory policy shifts, and cutting-edge research have all contributed to propelling this industry forward. This report delves into multiple facets of the market, providing an in-depth analysis of transformative shifts, segmentation nuances, regional market variations, competitive dynamics, and actionable guidance for industry leaders. By offering a balanced and detailed perspective that caters to both experts and seasoned professionals, the following sections shed light on the dramatic changes shaping the future of oncology therapeutics.

Transformative Shifts in the Oncology Drugs Landscape

Recent years have demonstrated transformative shifts in the oncology drugs landscape, where scientific breakthroughs and strategic partnerships have redefined treatment modalities. The integration of precision medicine and advancements in genomic profiling have revolutionized therapy selection, enabling personalized approaches that enhance treatment efficacy. Innovations in drug development have led to the emergence of targeted therapies and immuno-oncology agents, which have not only improved survival rates but also reduced toxicity compared to traditional chemotherapy. Moreover, a heightened focus on patient-centric care has driven the adoption of novel delivery methods that improve compliance and overall outcomes. Regulatory agencies across the globe have accelerated the evaluation process for breakthrough therapies, thereby expediting market access for promising compounds. This paradigm shift is marked by robust investment in research and development, a greater emphasis on real-world evidence, and collaborative initiatives between academia and industry. These changes have collectively set the stage for a competitive and innovative market landscape that is poised to meet the evolving demands of a diverse patient population.

Key Segmentation Insights Driving Market Dynamics

The oncology drugs market is distinguished by a complex segmentation framework that offers a granular view of the various therapeutic and commercial segments. When considering drug class, the analysis spans chemotherapy agents, hormonal therapy agents, immunotherapy agents, and targeted therapy agents. Within chemotherapy agents, detailed evaluation of alkylating agents and antimetabolites provides vital insights into the efficacy and toxicity profiles that impact clinical decisions. Immunotherapy agents are further segmented into CAR T-Cell Therapy and checkpoint inhibitors, with a focused examination on CTLA-4 inhibitors alongside PD-1/PD-L1 inhibitors, highlighting their differential roles in modulating immune responses. In the realm of targeted therapy, further scrutiny is given to monoclonal antibodies-with distinctions between chimeric and humanized-and small molecule inhibitors, where a nuanced review of cyclin-dependent kinase inhibitors and tyrosine kinase inhibitors is essential for understanding pharmacodynamics. Additionally, segmentation based on the route of administration differentiates injectable formulations, including intramuscular, intravenous, and subcutaneous options, from oral therapies. Evaluations of molecule type contrast the performance and application of biologics, comprising monoclonal antibodies and vaccines, against small molecules. Indication-based segmentation encompasses a range of cancers from blood, breast, colorectal, lung, to prostate, with further breakdowns in blood cancers into leukemia and lymphoma, and deeper distinctions within acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma. Insights extend to end-user segmentation involving hospitals, research institutes, and specialty clinics, as well as distribution channels that distinguish hospital pharmacies, online pharmacies, and retail pharmacies. This comprehensive panorama underscores the heterogeneity of the market while equipping stakeholders with targeted insights required for strategic decision-making.

Based on Drug Class, market is studied across Chemotherapy Agents, Hormonal Therapy Agents, Immunotherapy Agents, and Targeted Therapy Agents. The Chemotherapy Agents is further studied across Alkylating Agents and Antimetabolites. The Immunotherapy Agents is further studied across CAR T-Cell Therapy and Checkpoint Inhibitors. The Checkpoint Inhibitors is further studied across CTLA-4 Inhibitors and PD-1/PD-L1 Inhibitors. The Targeted Therapy Agents is further studied across Monoclonal Antibodies and Small Molecule Inhibitors. The Monoclonal Antibodies is further studied across Chimeric and Humanized. The Small Molecule Inhibitors is further studied across Cyclin-Dependent Kinase Inhibitors and Tyrosine Kinase Inhibitors.

Based on Route of Administration, market is studied across Injectable and Oral. The Injectable is further studied across Intramuscular, Intravenous, and Subcutaneous.

Based on Molecule Type, market is studied across Biologics and Small Molecules. The Biologics is further studied across Monoclonal Antibodies and Vaccines.

Based on Indication, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer. The Blood Cancer is further studied across Leukemia and Lymphoma. The Leukemia is further studied across Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia. The Lymphoma is further studied across Hodgkin Lymphoma and Non-Hodgkin Lymphoma.

Based on End User, market is studied across Hospitals, Research Institutes, and Specialty Clinics.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Key Regional Insights Shaping Global Market Trends

The global oncology drugs market is defined by distinct regional trends, where variations in regulatory frameworks, healthcare infrastructure, and population demographics play a critical role. In the Americas, robust investment in medical research and innovation, coupled with a well-established healthcare system, has catalyzed rapid adoption of new therapies. The region presents a fertile ground for advanced clinical trials and strategic partnerships, driving sustained growth in the sector. Europe, Middle East & Africa have also registered significant progress, with Western Europe and certain Middle Eastern economies leading innovations in drug approvals and reimbursement models. The region benefits from a collaborative environment between public institutions and private enterprises, fostering groundbreaking research and ensuring timely market access to novel therapeutics. In parallel, the Asia-Pacific region continues to offer an expansive consumer base complemented by rising healthcare expenditure and increasing government initiatives aimed at modernizing the healthcare sector. This convergence of factors across diverse geographical areas not only emphasizes the varied market dynamics but also suggests opportunities for tailored strategies that address both established and emerging markets.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights and Competitive Advantages

The competitive landscape in oncology drugs encompasses numerous industry leaders whose strategic initiatives and robust pipelines have significantly transformed the market. Prominent players such as AbbVie Inc., Agenus Inc., Amgen Inc., Apres-demain SA, Aspen Pharmacare Holdings Limited, and Astellas Pharma Inc. are at the forefront of pioneering innovative treatments with an emphasis on personalized care. Research and development giants, including AstraZeneca PLC, Bayer AG, and Bristol-Myers Squibb Company, have been instrumental in advancing immunotherapy and targeted therapy options. Meanwhile, companies like BeiGene, Inc., C.H. Boehringer Sohn AG & Co. KG, Cipla Limited, and Eli Lilly and Company continue to diversify their portfolios by merging traditional therapeutic methods with next-generation platforms. GSK plc, Johnson & Johnson Services, Inc., and Merck KGaA further reinforce this innovative spirit through collaborative ventures exploring novel molecular targets. Pfizer Inc., Puma Biotechnology, Inc., Roche Holding AG, Shorla Oncology, and Sun Pharmaceutical Industries Ltd also play key roles, alongside emerging firms such as Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc., whose nimble approaches and breakthrough research are reshaping treatment paradigms. Together, these companies represent a blend of legacy strength and innovative agility, collectively sustaining a competitive edge and driving overall market momentum.

The report delves into recent significant developments in the Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agenus Inc., Amgen Inc., Apres-demain SA, Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cipla Limited, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Merck KGaA, Pfizer Inc., Puma Biotechnology, Inc., Roche Holding AG, Shorla Oncology, Sun Pharmaceutical Industries Ltd, Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc.. Actionable Recommendations for Industry Leaders to Navigate Market Opportunities

Industry leaders are urged to adopt a forward-thinking stance that leverages technological advancements and evolving patient needs to capitalize on emerging opportunities in the oncology drugs market. First, it is essential to invest in integrated research initiatives that combine clinical insights with real-world data, thereby enabling effective patient segmentation and personalized therapy development. Collaborative partnerships and joint ventures between large-scale pharmaceutical companies and smaller biotech innovators can accelerate the discovery process while mitigating risk. Leaders should also consider expanding their presence in key regional markets by tailoring approaches to meet the unique regulatory and economic conditions prevalent in the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. Emphasizing digital transformation within supply chains and distribution channels, particularly through the adoption of online and retail pharmacy models, can enhance market reach and operational efficiency. Furthermore, maintaining adaptive strategies that anticipate shifts in drug development methodologies across various segmentation parameters-including drug class, route of administration, molecule type, indication, end user, and distribution channel-is crucial. A comprehensive understanding of competitive dynamics, combined with agile decision-making and continuous innovation, will ultimately serve as the cornerstone for sustainable growth and market leadership in this rapidly evolving field.

Conclusion: Reflecting on the Multifaceted Dynamics of Oncology Drug Innovations

In summary, the oncology drugs market stands as a testament to transformative progress achieved through scientific brilliance and strategic foresight. The evolving therapeutic landscape, marked by advances in targeted therapies and personalized medicine, reflects not only a commitment to improved patient outcomes but also highlights the complex interplay of regulatory, clinical, and technological factors driving growth. The segmented analysis of various drug classes, routes of administration, molecule types, indications, end-user profiles, and distribution channels provides a comprehensive view that is indispensable for understanding the underlying market dynamics. Moreover, regional insights reinforce the diverse settings in which these innovations are being adopted, while competitive company insights expose the multifaceted strategies employed by industry frontrunners. As the market continues to transform, the integration of data-driven approaches and collaborative frameworks will remain essential for fostering further advancements. This report underscores the critical need to stay agile and informed as we navigate the future course of oncology therapeutics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing governmental support through favorable reimbursement policies for cancer drugs
    • 5.1.1.2. Rising investments in cancer research and development activities from both public and private sectors
    • 5.1.1.3. Increasing prevalence of various types of cancers worldwide demands a surge in oncology drug development
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with cancer treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased collaboration with biotech firms to fast-track development of innovative oncology drugs
    • 5.1.3.2. Integrating telemedicine with oncology practices to reach underserved and remote patient populations
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity associated with conducting oncology drug trials
• 5.2. Market Segmentation Analysis
  • 5.2.1. Route of Administration: Rising preference for injectable routes due to its rapid delivery of chemotherapeutic agents
  • 5.2.2. End User: Rising use of oncology drugs in hospitals due to high volume of cancer patients
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oncology Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Chemotherapy Agents
  • 6.2.1. Alkylating Agents
  • 6.2.2. Antimetabolites
• 6.3. Hormonal Therapy Agents
• 6.4. Immunotherapy Agents
  • 6.4.1. CAR T-Cell Therapy
  • 6.4.2. Checkpoint Inhibitors
    • 6.4.2.1. CTLA-4 Inhibitors
    • 6.4.2.2. PD-1/PD-L1 Inhibitors
• 6.5. Targeted Therapy Agents
  • 6.5.1. Monoclonal Antibodies
    • 6.5.1.1. Chimeric
    • 6.5.1.2. Humanized
  • 6.5.2. Small Molecule Inhibitors
    • 6.5.2.1. Cyclin-Dependent Kinase Inhibitors
    • 6.5.2.2. Tyrosine Kinase Inhibitors

7. Oncology Drugs Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable
  • 7.2.1. Intramuscular
  • 7.2.2. Intravenous
  • 7.2.3. Subcutaneous
• 7.3. Oral

8. Oncology Drugs Market, by Molecule Type

• 8.1. Introduction
• 8.2. Biologics
  • 8.2.1. Monoclonal Antibodies
  • 8.2.2. Vaccines
• 8.3. Small Molecules

9. Oncology Drugs Market, by Indication

• 9.1. Introduction
• 9.2. Blood Cancer
  • 9.2.1. Leukemia
    • 9.2.1.1. Acute Myeloid Leukemia
    • 9.2.1.2. Chronic Lymphocytic Leukemia
  • 9.2.2. Lymphoma
    • 9.2.2.1. Hodgkin Lymphoma
    • 9.2.2.2. Non-Hodgkin Lymphoma
• 9.3. Breast Cancer
• 9.4. Colorectal Cancer
• 9.5. Lung Cancer
• 9.6. Prostate Cancer

10. Oncology Drugs Market, by End User

• 10.1. Introduction
• 10.2. Hospitals
• 10.3. Research Institutes
• 10.4. Specialty Clinics

11. Oncology Drugs Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Hospital Pharmacies
• 11.3. Online Pharmacies
• 11.4. Retail Pharmacies

12. Americas Oncology Drugs Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Oncology Drugs Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Oncology Drugs Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. AstraZeneca gets the nod to launch cancer drug
  • 15.3.2. Lupin's strategic US launch of cost-effective generic doxorubicin targets key oncology markets
  • 15.3.3. FDA approves novel IL-15 receptor agonist for enhancing response in BCG-unresponsive NMIBC treatment
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Agenus Inc.
• 3. Amgen Inc.
• 4. Apres-demain SA
• 5. Aspen Pharmacare Holdings Limited
• 6. Astellas Pharma Inc.
• 7. AstraZeneca PLC
• 8. Bayer AG
• 9. BeiGene, Inc.
• 10. Bristol-Myers Squibb Company
• 11. C.H. Boehringer Sohn AG & Co. KG
• 12. Cipla Limited
• 13. Eli Lilly and Company
• 14. GSK plc
• 15. Johnson & Johnson Services, Inc.
• 16. Merck KGaA
• 17. Pfizer Inc.
• 18. Puma Biotechnology, Inc.
• 19. Roche Holding AG
• 20. Shorla Oncology
• 21. Sun Pharmaceutical Industries Ltd
• 22. Sutro Biopharma, Inc.
• 23. Takeda Pharmaceutical Company Limited
• 24. Viatris Inc.